News Release

Therole of fatty acids in Multiple Myeloma Microenvironments isinvestigated through the use of Cleanascite™

MONMOUTHJUNCTION, NJ, January31, 2023 -- Biotech Support Group reports on an article, describingthe simplicity and efficiency of their lipid binding technology todetermine the influence long-chain fatty acids on CD8+ T cellmetabolism and function in Multiple Myeloma.

Gudgeon,Bishop, et al. "CD8+T cell metabolism and function are suppressed by long-chain fattyacid uptake from the bone marrow microenvironment in MultipleMyeloma."(2023).

MultipleMyeloma (MM) is a plasma cell malignancy that develops in the bonemarrow. Function of T lymphocytes is impaired in patients with MM andthe bone marrow microenvironment is described as hostile for T cellactivity. Precise suppressive mechanisms within the bone marrowmicroenvironment remain poorly defined.Inthis study T cell phenotype, function and metabolic activity wereanalysed within paired bone marrow aspirate and peripheral bloodsamples from 72 patients across the spectrum of MM.Thebone marrow microenvironment was also modelled in vitro usingautologous plasma co-culture systems.

Invitro modelling confirmed that uptake of bone marrow lipidssuppresses CD8 + T function, which was impaired in autologous bonemarrow plasma, but rescued by both lipid removal and inhibition oflipid peroxidation. Thearticle states “Removalof BM lipids (using Cleanascite) increased mitochondrial mass incontrol and MM BM CD8 + T cells (Fig.), accompanied by restoration ofIFN-γ and TNF-α expression.”. The article concludes that CD8 + Tcells are functionally impaired within the MM bone marrowmicroenvironment. This is accompanied by decreased mitochondrial massbut elevated uptake of long-chain fatty acids. Blockade of fatty acidtransport protein 1 (FATP1) restores CD8 + T cell function inpresence of BM lipids and may therefore represent a novel therapeutictarget to augment their activity in the bone marrow in MM and improveefficacy of T cell directed therapies. 

“Thisis now our sixth study whereby Cleanascite™ was used in evaluatingtheremoval of free fatty acids in for invitrocancer models.These references along with over twenty others, show thatCleanascite™ can help identify a characteristic feature of cellresponse related to lipid removal. Unlike alternative methods thatuse solvents, Cleanascite™ is an aqueous suspension product and sopost-treatment, it is seamlessly integrates with cellular models ofdisease. This ultimately helps with investigations such as this, thatneed to determine whether or not lipids, or factors associated withlipids, impart phenotypic changes to cells.” states Swapan Roy,Ph.D., President and Founder of Biotech Support Group.

Linkto view our case study, LipidRemoval for Phenotypic Cell Response in Cancer Research(biotechsupportgroup.com)

Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords:MultipleMyeloma, CD8+ T cell, long-chain fatty acids, lipid removal,mitochondria, bone marrow microenvironment, Cleanascite™

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal.From these innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com.

ForBusiness Development,contact:MatthewKuruc 732-274-2866, [email protected]